Latest Insights - page 53 | BiopharmaTrend

XtalPi’s Ailux Biologics Enters License Agreement with Janssen Biotech to Advance AI-Powered Biologics Discovery

XtalPi Inc., an AI-driven R&D platform company, announced that its division, Ailux Biologics, has entered into a non-exclusive license agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. …

Continue ›››

Google Research and DeepMind Unveil Tx-LLM: A New Language Model for Therapeutic Development

Google Research and DeepMind have introduced Tx-LLM, a language model designed to predict the properties of biological entities throughout the drug discovery process. Tx-LLM, which was developed based on the …

Continue ›››

Recursion Pharmaceuticals Receives FDA Clearance for AI-Discovered Cancer Drug Trial

Recursion Pharmaceuticals announced that it has received FDA clearance to begin clinical trials for REC-1245, an investigational drug targeting solid tumors and lymphoma. The company, known for its AI-enabled drug …

Continue ›››

BioPharmCatalyst Launches "Aiden," AI Chatbot for Biotech Investors

BioPharmCatalyst, a division of Scientist.com, has launched a new AI-powered chatbot named "Aiden" to deliver personalized customer service and support for biotech investors. Aiden utilizes the latest advancements in large …

Continue ›››

The Promise of Chatbots in Clinical Trials

In the rapidly changing field of clinical trials, chatbots are becoming valuable tools for data analysis. These AI-driven conversational agents streamline data collection, boost patient engagement, and enhance the accuracy …

Continue ›››

Proscia Releases Concentriq Embeddings and AI Toolkit for Digital Pathology Research

Proscia has introduced Concentriq Embeddings and the Proscia AI Toolkit as part of its Concentriq platform, providing technical resources for AI model development in digital pathology. These tools are designed …

Continue ›››

Even 10 Minutes Matter in Cancer Research

A recent study conducted by Indivumed Therapeutics highlights a crucial, yet often overlooked, factor in cancer research: the cold ischemia time (CIT), or the time it takes to preserve tumor …

Continue ›››

This Company Sets a New Milestone with World’s First Human Graphene Brain-Computer Interface

INBRAIN Neuroelectronics has announced the successful completion of the world’s first human procedure using their graphene-based brain-computer interface (BCI), a key milestone in the advancement of neurotechnology. This procedure, performed …

Continue ›››

How Enterprise Architecture is Powering Digital Transformation in Healthcare

The healthcare industry is confronting critical challenges including a systemic labour shortage, rising costs (estimated to grow to its highest level in 13 years) and regulatory pressures. In PwC’s 26th …

Continue ›››

CluePoints Introduces Medical & Safety Review Tool to Optimize Clinical Data Management

CluePoints has launched the Medical & Safety Review (MSR) software, a new tool aimed at addressing inefficiencies in clinical data review and enhancing the transparency of safety assessments during clinical …

Continue ›››

BioAge Labs Targets Obesity with Upsized IPO, Expected to Raise $198M to Fund Clinical Trials

BioAge Labs (Richmond, CA), a clinical-stage biopharmaceutical company developing therapies for metabolic diseases such as obesity, has announced the pricing of its upsized initial public offering (IPO). The company expects …

Continue ›››

Immunai and AstraZeneca Collaborate to Optimize Oncology Clinical Trials Using AI-driven Immune Mapping

Immunai, a New York-based AI biotech company, has entered a multi-year collaboration with AstraZeneca to optimize oncology clinical trials. This partnership will use Immunai’s proprietary AMICA platform and Immunodynamics Engine …

Continue ›››